HERG Screening Market Research Report - Global Forecast till 2027

HERG Screening Market: Information By Type (Gene KCNH2, Mutant KCNH2), Ion Channel (Voltage-gated ion channel, Ligand-gated ion channel), Application (Antiarrhythmic, Antipsychotic, Antibiotics) and Region (Americas, Europe, Asia-Pacific and the Middle East and Africa) - Global Forecast till 2027

ID: MRFR/HC/8908-CR | January 2021 | Region: Global | 107 pages


Global hERG Screening Market is expected to register a CAGR of 13.85% during the assessment period of 2020 to 2027, to reach USD 3,304.58 Million by 2027. hERG screening has been an important component of cardiac safety-pharmacology from the past many years. hERG was identified as a potassium-selective cardiac ion channel, Kv11.1, which plays an important role during cardiac repolarization.

Market Dynamics

The increasing novel drug approvals and the growing prevalence of heart diseases are driving the global hERG screening market. However, the high cost of hERG screening products is expected to hamper the growth of this market during the forecast period. Nevertheless, untapped markets are likely to set a lucrative opportunity for the growth of this market in the near future.

hERG screening is primarily used for the drug discovery process. The increasing number of product launches is anticipated to boost the demand for hERG screening in the coming years. According to the annual report published by the Center for Drug Evaluation and Research (CDER), an estimated 25 drugs received novel drugs approval for marketing in 2016, whereas 59 in 2018. The increasing number of novel drugs approvals is expected to support the drugs discovery process that helps the hERG screening market to grow.


Global hERG Screening Market is segmented based on Type into ion Channel and Application.

The hERG screening market, on the basis of type, has been segmented into gene KCNH2 and mutant KCNH2. KCNH2 gene that provides guidelines for producing potassium channels, where this channel transports positively charged atoms of potassium out of the cells and plays a key role in generating & transmitting electrical signals. The mutation in KCNH2 causes cardiac arrhythmia. Similarly, long QT syndrome is caused by mutations in KCNH2, where an estimated 1 in 5,000–10,000 people suffered from long QT syndrome across the globe.

The global hERG screening market is segmented, based on the ion channel, into voltage-gated ion channel, ligand-gated ion channel, and others. Voltage gated ion channel held the largest share of the hERG screening market, whereas ion gated channel is the fastest-growing segment. The major factors attributed to the market growth of this segment are screening of drugs for (Human Ether-a-go-go related gene) hERG in early stages of drug discovery and development, robust growth in the pharmaceutical companies for hERG screening of lead compounds, and challenges in developing products useful for pharmaceutical and biotechnology applications.

The application segment is divided into antiarrhythmic drugs, antipsychotics, antibiotics, and others. The antiarrhythmic drug application segment is projected to hold a considerable market share. Increasing demand for drug modulation ion channel activity for its application in cardiovascular disorders, metabolic disorders, and oncology are boosting the growth of the hERG screening market.

Regional Analysis

Global hERG Screening Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas market has been segmented into North America and Latin America, with North America further divided into the US and Canada. The European hERG screening market has been segmented into Western Europe and Eastern Europe. The Western Europe hERG screening market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The hERG screening market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The Middle East & Africa hERG screening market has been divided into the Middle East and Africa.

The Americas held the largest market share of 37.3% of the hERG screening market in 2019. This share can be attributed to technological development and the high prevalence of cardiac disease in the region. In 2017, according to the American College of Cardiology, emergency medical services-assessed out-of-hospital cardiac arrest occurred in an estimated 356,461 Americans. Similarly, increasing novel drug launches will support the growth of the market. According to the annual report published by the Center for Drug Evaluation and Research (CDER), an estimated 25 drugs received novel drugs approval for marketing in 2016, whereas 59 in 2018. These factors are likely to boost the growth of the market during forecast period

Key Players

The Prominent Players in the Global hERG Screening Market are Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Metrion biosciences, and Aurora Biomed. Some of the key strategies followed by players operating in the Global hERG screening market are FDA approvals, joint ventures, acquisitions, expansions, and collaborations.

  • In March 2020, Charles River Laboratories entered a partnership with Deciphex, a leader in preclinical digital pathology software-as-a-service. In addition to Charles River being the exclusive contract research organization distributing the Patholytix preclinical solution to clients, the organizations will work together to co-develop deep learning-enabled tools to support accelerated pathology analytics.

  • In July 2017, Eurofins Scientific announced the acquisition of Discover X, a leader in drug discovery products and services across all stages of discovery from target identification and lead discovery to preclinical and beyond.

Market Segmentation

Global HERG Screening Market, By Type

  • Gene KCNH2

  • Mutant KCNH2

Global HERG Screening Market, By Ion Channel

  • Voltage Gated

  • Ligand Gated

Global HERG Screening Market, By Application

  • Antiarrhythmic

  • Antipsychotic

  • Antibiotics

  • Others

Global HERG Screening Market, By Region

  • Americas

    • North America

      • US

      • Canada

    • Latin America

  • Europe

    • Western Europe

      • Germany

      • France

      • UK

      • Italy

      • Spain

      • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Middle East & Africa

    • Middle East

    • Africa

Available Additional Customizations

  • Impact of COVID-19 on the hERG Screening Market

  • Mega Trends in the Market

  • Investment Opportunities

  • Pricing Analysis

Intended Audience

  • Pharmaceutical companies

  • Research & development organizations

  • Academic institutes

Report Scope:
Report Attribute/Metric Details
  Market Size   2027: USD 3,304.58 Million
  CAGR   13.85% (2020-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Ion Channel, Application
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Metrion biosciences, and Aurora Biomed
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing novel drug approvals
  • Growing prevalence of heart diseases

  • This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.